Julian Harrison
Stock Analyst at BTIG
(4.61)
# 214
Out of 5,154 analysts
97
Total ratings
58.89%
Success rate
23.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Maintains: Buy | $40 → $21 | $13.58 | +54.64% | 5 | Mar 3, 2026 | |
| INVA Innoviva | Reiterates: Buy | $35 | $22.18 | +57.80% | 2 | Feb 26, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $5 → $4 | $1.19 | +236.13% | 4 | Feb 25, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Buy | $150 | $112.70 | +33.10% | 5 | Feb 25, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $24 → $30 | $18.02 | +66.48% | 5 | Feb 23, 2026 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $70 | $40.59 | +72.46% | 5 | Feb 20, 2026 | |
| ARDX Ardelyx | Reiterates: Buy | $17 | $6.27 | +171.13% | 3 | Feb 20, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $118 → $151 | $72.45 | +108.42% | 4 | Feb 10, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $37 → $46 | $45.30 | +1.55% | 4 | Jan 16, 2026 | |
| MREO Mereo BioPharma Group | Reiterates: Buy | $1 | $0.39 | +155.75% | 3 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $34.52 | +41.95% | 6 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $63 → $73 | $33.17 | +120.08% | 4 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.13 | +59.74% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $137 | $70.92 | +93.18% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $15.60 | +143.59% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $6.88 | +539.53% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.46 | +306.50% | 2 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $28.96 | +110.64% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $91.41 | -10.29% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $7.39 | +8.25% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $4.02 | +273.13% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.88 | +101.73% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.58 | +127.53% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.71 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.28 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.43 | +1,984.30% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $3.12 | +156.41% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.58 | +1,273.39% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.58 | +25,941.67% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $485.06 | - | 2 | Feb 11, 2022 |
Theravance Biopharma
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $21
Current: $13.58
Upside: +54.64%
Innoviva
Feb 26, 2026
Reiterates: Buy
Price Target: $35
Current: $22.18
Upside: +57.80%
Akebia Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $1.19
Upside: +236.13%
ABIVAX Société Anonyme
Feb 25, 2026
Reiterates: Buy
Price Target: $150
Current: $112.70
Upside: +33.10%
MoonLake Immunotherapeutics
Feb 23, 2026
Maintains: Buy
Price Target: $24 → $30
Current: $18.02
Upside: +66.48%
Spyre Therapeutics
Feb 20, 2026
Reiterates: Buy
Price Target: $70
Current: $40.59
Upside: +72.46%
Ardelyx
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $6.27
Upside: +171.13%
Nektar Therapeutics
Feb 10, 2026
Maintains: Buy
Price Target: $118 → $151
Current: $72.45
Upside: +108.42%
Maze Therapeutics
Jan 16, 2026
Maintains: Buy
Price Target: $37 → $46
Current: $45.30
Upside: +1.55%
Mereo BioPharma Group
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.39
Upside: +155.75%
Jan 13, 2026
Reiterates: Buy
Price Target: $49
Current: $34.52
Upside: +41.95%
Jan 12, 2026
Maintains: Buy
Price Target: $63 → $73
Current: $33.17
Upside: +120.08%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $3.13
Upside: +59.74%
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $137
Current: $70.92
Upside: +93.18%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $15.60
Upside: +143.59%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.88
Upside: +539.53%
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.46
Upside: +306.50%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $28.96
Upside: +110.64%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $91.41
Upside: -10.29%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $7.39
Upside: +8.25%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $4.02
Upside: +273.13%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $13.88
Upside: +101.73%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $17.58
Upside: +127.53%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.71
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $57.28
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.43
Upside: +1,984.30%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.12
Upside: +156.41%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.58
Upside: +1,273.39%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.58
Upside: +25,941.67%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $485.06
Upside: -